ARCH Venture Management, LLC Diversified Active

CIK: 0001274403 · Show all filings

Period: Q1 2024 (← Previous) (Next →)

Filing Date: May 15, 2024

Total Value ($000): $80,277 (100.0% shares, 0.0% debt)

Holdings (8)

— VERVE THERAPEUTICS, INC. 33.2%

Value ($000) $26,677 Shares 2,008,809 Est. Cost $36.87 Unrealized —

ERAS ERASCA, INC. 28.4%

Value ($000) $22,774 Shares 11,055,554 Est. Cost $17.12 Unrealized -88.3%

GOSS GOSSAMER BIO, INC. 11.8%

Value ($000) $9,506 Shares 8,055,916 Est. Cost $1.15 Unrealized -4.5%

DNLI DENALI THERAPEUTICS, INC. 9.7%

Value ($000) $7,823 Shares 381,249 Est. Cost $26.20 Unrealized -28.3%

QTTB Q32 BIO INC. 6.8%

Value ($000) $5,461 Shares 320,482 Est. Cost $13.78 Unrealized 0.0%

— CERO THERAPEUTICS HOLDINGS, INC. 5.5%

Value ($000) $4,434 Shares 1,444,296 Est. Cost $3.07 Unrealized —

— SINGULAR GENOMICS SYSTEMS, INC. 2.4%

Value ($000) $1,953 Shares 3,798,926 Est. Cost $11.56 Unrealized —

— UNITY BIOTECHNOLOGY, INC. 2.1%

Value ($000) $1,648 Shares 1,004,817 Est. Cost $0.40 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	VERVE THERAPEUTICS, INC.	2,008,809	$26,677	33.2%	$36.87	—	COM	92539P101
ERAS	ERASCA, INC.	11,055,554	$22,774	28.4%	$17.12	-88.3%	COM	29479A108
GOSS	GOSSAMER BIO, INC.	8,055,916	$9,506	11.8%	$1.15	-4.5%	COM	38341P102
DNLI	DENALI THERAPEUTICS, INC.	381,249	$7,823	9.7%	$26.20	-28.3%	COM	24823R105
QTTB	Q32 BIO INC.	320,482	$5,461	6.8%	$13.78	0.0%	COM	746964105
—	CERO THERAPEUTICS HOLDINGS, INC.	1,444,296	$4,434	5.5%	$3.07	—	CLASS A COM	71902K105
—	SINGULAR GENOMICS SYSTEMS, INC.	3,798,926	$1,953	2.4%	$11.56	—	COM	82933R100
—	UNITY BIOTECHNOLOGY, INC.	1,004,817	$1,648	2.1%	$0.40	—	COM	91381U200